Aurora Cannabis (NASDAQ:ACB) Posts Earnings Results, Beats Estimates By $0.14 EPS

Aurora Cannabis (NASDAQ:ACB) released its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.14, Zacks reports. Aurora Cannabis had a positive return on equity of 0.10% and a negative net margin of 33.57%.The firm had revenue of $60.98 million during the quarter, compared to analyst estimates of $54.42 million.

Here are the key takeaways from Aurora Cannabis’ conference call:

• Aurora said fiscal 2026 was a strong year, with net revenue up 11% to CAD 321 million, adjusted EBITDA up 32% to CAD 54 million, and adjusted net income improving by more than CAD 12 million versus the prior year.
• The company emphasized its global medical cannabis leadership, noting that about 55% of revenue came from outside Canada and that it holds leading positions in Canada, Germany, Australia, and Poland.
• Aurora is intentionally exiting lower-margin Canadian consumer and plant propagation businesses to reallocate capital toward higher-return international medical opportunities, though management said this will create a near-term revenue reset in FY2027.
• The company highlighted the Safari Flower acquisition and the Leuna expansion in Germany as steps to expand EU GMP capacity, with Safari expected to contribute positive adjusted EBITDA in FY2027 and more meaningfully thereafter.
• FY2027 guidance calls for lower revenue and lower annual adjusted EBITDA, mainly because of Canada’s reimbursed pricing change, which management said will reduce Canadian medical revenue and gross profit but be partly offset by international growth.

Aurora Cannabis Trading Down 1.3%

Shares of ACB stock opened at $3.04 on Friday. Aurora Cannabis has a 1 year low of $2.73 and a 1 year high of $6.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 1.48. The stock’s 50 day simple moving average is $3.45 and its two-hundred day simple moving average is $3.84. The company has a market cap of $186.47 million, a PE ratio of -1.95 and a beta of 0.53.

Institutional Investors Weigh In On Aurora Cannabis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACB. Jones Financial Companies Lllp raised its position in Aurora Cannabis by 9,615.6% during the first quarter. Jones Financial Companies Lllp now owns 52,270 shares of the company’s stock valued at $229,000 after purchasing an additional 51,732 shares during the period. Goldman Sachs Group Inc. raised its position in Aurora Cannabis by 4.1% during the first quarter. Goldman Sachs Group Inc. now owns 743,903 shares of the company’s stock valued at $3,266,000 after purchasing an additional 29,099 shares during the period. Engineers Gate Manager LP purchased a new stake in Aurora Cannabis during the second quarter valued at approximately $68,000. Tidal Investments LLC raised its position in Aurora Cannabis by 6.0% during the second quarter. Tidal Investments LLC now owns 1,509,483 shares of the company’s stock valued at $6,400,000 after purchasing an additional 86,045 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Aurora Cannabis during the second quarter valued at approximately $66,000. 47.63% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ACB. Weiss Ratings raised Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Wall Street Zen raised Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.